News

News 07.01.2021 Zurich-Schlieren, Switzerland, January 07, 2021 - Proteomedix, the Swiss cancer diagnostics company, announced today that the results of PROPOSe, a prospective multicenter study of Proclarix® in clinical routine use, were published in European Urology Oncology1). Prostate specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or...

News 04.01.2021 OAKLAND, N.J., Dec. 29, 2020 /PRNewswire/ -- Collagen Matrix, Inc., a global leader in regenerative, collagen-based, xenograft-derived medical devices, and portfolio company of Linden Capital Partners ("Linden"), announced today the acquisition of Sunstar's Degradable Solutions division (the "Company"), including its GUIDOR® branded line of resorbable synthetic medical implants. Founded in 1999, Degradable Solutions AG, is...

News 17.12.2020 Zurich-Schlieren, Switzerland, December 17, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio...

News 10.12.2020 Schlieren and St. Gallen, Switzerland, December 10, 2020 - The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced that Prof. Dr. med. Wolfang Korte who leads the Center for Laboratory Medicine will present new data from the implementation of Proclarix® in their laboratory...

News 02.12.2020 Zurich-Schlieren, Switzerland and Frankfurt am Main, Germany, December 2, 2020 - The University Hospital Frankfurt MVZ (Medical Outpatient Care Center) GmbH, and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, is made routinely available in Germany. ”Proclarix is an innovative...